Mast cell tumours in dogs: signs, tests, grades and treatment

A mast cell tumour is a cancer formed from mast cells, which are immune cells that normally store substances involved in inflammation.

In dogs, these tumours most often develop in or beneath the skin. Their behaviour ranges widely: some remain local and respond well to treatment, while others grow aggressively or spread, so the diagnosis alone does not predict the whole course. [1]

No. Mast cell tumours range from slow-growing, lower-grade growths to aggressive tumours that enlarge quickly, ulcerate or spread.

The name of the tumour therefore cannot give an individual dog's outlook. Microscopic grade, stage, location, growth pattern and the completeness of any surgical removal all contribute to the veterinary team's assessment of likely behaviour. [1]

A cutaneous mast cell tumour is centred in the skin, while a subcutaneous tumour is centred in the tissue beneath it.

That distinction is made accurately on histopathology, not by touch alone. Subcutaneous tumours often behave less aggressively as a group, but some recur or spread, so depth is useful context rather than a complete prediction for an individual dog. [1]

A mast cell tumour has no single reliable appearance: it may be raised or flat, firm or soft, inflamed or outwardly quiet.

A tumour beneath the skin can resemble a fatty lipoma, while another may be hairless, reddened or ulcerated. Looking and feeling cannot identify the cells involved, which is why a sample matters even when a lump appears harmless. [2]

Yes. A mast cell tumour can become larger and smaller as inflammation around it changes, sometimes over a short period.

This fluctuation can happen when tumour cells release inflammatory granules into nearby tissue. A reduction in size does not mean the mass has disappeared or become harmless, and a changing lump still merits veterinary assessment. [3]

Rubbing or manipulating a mast cell tumour can trigger release of histamine and other stored substances, causing temporary redness, itching or swelling.

This reaction is called degranulation. Repeated squeezing, rubbing or attempting to drain the lump is not appropriate; the important next step is veterinary assessment and controlled sampling rather than judging the mass from how it reacts. [4]

Yes. Some dogs appear well and have only a small, movable skin or under-skin lump with little surrounding inflammation.

Feeling well does not reveal the tumour's grade or confirm that a lump is benign. Mast cell tumours can resemble non-cancerous growths, so the absence of pain or illness should not be used to decide whether a new mass needs checking. [3]

A mast cell tumour can contribute to vomiting, reduced appetite or abdominal pain because released histamine may damage the stomach and intestinal lining.

These signs have many other possible causes, but in a dog with a known or suspected mast cell tumour they warrant urgent veterinary contact. The combination can indicate effects beyond the visible skin lump and may change the assessment plan. [3]

Black, tarry stool can represent digested blood from gastrointestinal ulceration and needs urgent veterinary assessment in a dog with a mast cell tumour.

Histamine released by mast cell disease can increase stomach acid and injure the gastrointestinal lining. Dark stool may be accompanied by vomiting, poor appetite, abdominal discomfort, weakness or anaemia, but it can be important even without every other sign. [3]

Yes. Collapse, marked weakness, breathing difficulty or pale gums in a dog with a known or suspected mast cell tumour requires emergency veterinary help immediately.

Mast-cell mediator release can rarely cause severe whole-body effects, while collapse also has other life-threatening causes. The visible lump may seem unchanged, so the dog's overall condition is the reason for emergency escalation rather than the mass's appearance. [5]

A new or changing lump on a dog should be checked by a vet promptly, even when it seems small, soft or harmless.

Mast cell tumours do not share one dependable appearance and can mimic benign growths. Earlier sampling can establish what cells are present and helps the veterinary team plan appropriately before a mass becomes larger, inflamed or harder to remove. [6]

A red, itchy, ulcerated or fast-growing lump needs veterinary assessment promptly because these changes can occur with a mast cell tumour.

Inflammation does not prove the diagnosis, and other skin conditions can look similar. Rapid enlargement, surface damage, bleeding or persistent irritation nevertheless make passive observation unsuitable and may affect how the mass can be sampled or removed. [6]

A mast cell tumour is usually identified by examining cells collected from the lump with a fine-needle aspirate.

The small sample is spread on a microscope slide, where mast cells often have distinctive coloured granules. The procedure commonly provides a diagnosis from the visible mass, although the veterinary team may need further testing when the cells are poorly granulated or unclear. [3]

An unclear needle sample does not confirm that a dog's lump is benign; some mast cell tumours lack the obvious granules that usually make them easy to recognise.

The next diagnostic step depends on the sample quality and clinical picture. A veterinary pathologist may use additional laboratory assessment, or the vet may obtain tissue for histopathology so the mass can be identified and characterised more reliably. [3]

A fine-needle aspirate can often identify mast cells, but definitive grading of a skin mast cell tumour relies on histopathology of tissue.

A cell sample does not preserve the tissue architecture needed for the established grading systems. Cytological grading approaches may offer preliminary information, but the expert consensus treats microscopic examination of a biopsy or removed tumour as the grading standard. [1]

Histopathology confirms the tumour type, assigns its microscopic grade and assesses the edges of the removed tissue for tumour cells.

Those findings help estimate local recurrence and spread risk and show whether surgery appears complete. The report is interpreted alongside the tumour's site, size, clinical behaviour and staging results rather than being treated as an isolated label. [3]

Tumour grade describes microscopic features linked with how aggressively a cutaneous mast cell tumour may behave.

A pathologist assesses features such as tissue invasion, cell shape and the number of dividing cells. Lower-grade tumours generally carry a more favourable outlook than higher-grade tumours, but grade is interpreted with stage, location, margins and the dog's clinical picture. [3]

A pathology report may give both Patnaik and Kiupel grades because the systems group cutaneous mast cell tumours differently and provide complementary context.

Patnaik uses three categories, while Kiupel uses low and high grade. The oncology-pathology consensus recommends reporting both systems, helping the veterinary team interpret a tumour without forcing every case into a single descriptive scale. [7]

No. Grade is an important risk marker, but it cannot predict an individual mast cell tumour's behaviour with certainty.

Some tumours with reassuring microscopic features still act aggressively. Age, growth pattern, size, anatomical site, stage, surgical margins and additional pathology markers all add context, so prognosis should come from the whole case rather than one word on the report. [7]

Stage describes the extent of mast cell tumour disease and whether it is confined to the original site or found elsewhere.

It answers a different question from microscopic grade. Staging findings help the veterinary team understand spread, plan local or systemic treatment and frame the outlook alongside pathology rather than assuming every visible skin tumour has the same reach. [1]

Staging may combine a full examination with blood tests, lymph-node sampling and selected imaging or organ samples to look for spread.

The exact set is chosen for the individual tumour and dog. Results can show whether disease appears local, involves a draining lymph node or has reached internal organs, and they provide context for treatment planning and prognosis. [1]

No. The extent of staging is tailored to the tumour's pathology, location, examination findings and other signs of possible spread.

Expert consensus does not support routine full abdominal and chest staging after removal of an otherwise uncomplicated low-grade skin or under-skin tumour, while higher-risk findings can justify broader investigation. The draining lymph node remains an important part of assessment. [1]

A normal-sized lymph node can still contain metastatic mast cells, so size and touch alone cannot rule out spread.

When lymph-node assessment is relevant, a needle sample or tissue examination can provide information that physical examination cannot. This is particularly important because regional or sentinel lymph nodes are often the first place a cutaneous mast cell tumour spreads. [1]

The sentinel lymph node is the first node in the lymphatic drainage pathway from a tumour, and it is not always the nearest node by anatomy.

Mapping that drainage can help the veterinary team choose the most informative node to sample. Selecting a node only because it sits closest to the lump may miss the route the tumour actually uses to spread. [1]

When a cutaneous mast cell tumour spreads, the sentinel or regional lymph node is commonly involved before internal organs such as the spleen and liver.

More distant organ and bone-marrow involvement can occur later, whereas lung involvement is very rare. This pattern explains why lymph-node assessment and abdominal evaluation may be more informative than assuming every cancer primarily spreads to the lungs. [1]

Surgical removal is the main local treatment for a removable canine mast cell tumour.

The operation is planned around the tumour's location and expected microscopic extension into nearby tissue. The removed mass is then examined by a pathologist for confirmation, grade and margins, which helps determine whether surgery alone is likely to be enough. [3]

The surgical wound can be larger than the visible mast cell tumour because the surgeon may remove a surrounding border and deeper tissue with it.

Mast cell tumour cells can extend microscopically beyond what can be seen or felt. Planning space around the mass aims to improve local control, but the achievable margin also depends on body site and nearby structures, so operations are individualised. [6]

Incomplete margins mean tumour cells reach a cut edge of the submitted tissue, suggesting microscopic disease may remain at the surgical site.

That finding does not mean regrowth is certain. Grade, site and other pathology details shape the next discussion, which may include further surgery, radiotherapy, systemic treatment or structured surveillance depending on the individual balance of risks. [3]

Additional treatment may be considered when a mast cell tumour cannot be fully removed, has higher-risk pathology or has spread beyond its original site.

Radiotherapy mainly supports local control in selected cases, while chemotherapy and targeted medicines address systemic or higher-risk disease. These categories are not interchangeable, and the choice depends on grade, stage, margins, tumour location and the dog's wider health. [3]

A veterinary team may use supportive medicines to reduce effects of histamine release, such as inflammation around the tumour or irritation of the stomach.

These medicines manage mediator-related effects rather than removing the cancer itself. Whether they are appropriate depends on the dog's signs, tumour burden and treatment plan; the underlying tumour still requires its own diagnostic and oncology decisions. [6]

Follow-up is tailored to the tumour's grade, stage, margins and treatment, and it includes checking the surgical area, relevant lymph nodes and the rest of the skin.

Dogs that have had one mast cell tumour can develop another, so each newly noticed lump deserves its own assessment rather than being assumed to be scar tissue, recurrence or the same harmless type as a previous mass. [2]

The outlook varies widely: many localised tumours can be removed and cured, while aggressive or metastatic disease is harder to control.

A useful individual estimate needs the tumour's size, site, cutaneous or subcutaneous location, microscopic grade, surgical margins and staging results. Response to treatment and the dog's general health add further context, so broad internet survival figures are not personal forecasts. [2]